Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of anisodine hydrobromide injection in acute ischemic stroke
ChiCTR2300074040Phase 3Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing anisodine hydrobromide + standard IV thrombolysis with Control: placebo + standard IV thrombolysis (2 arms). Primary endpoint: Proportion of subjects with mRS score 0–1 at day 90 ± 7. Started Jul 2023; status: recruiting.
02
Drugs
anisodine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2300074040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074040.